Clinical Data Highlights Caplyta as a Promising Option for Achieving Remission in Adults With Major Depressive Disorder
January 17, 2026
January 17, 2026
RARITAN, New Jersey, Jan. 17 -- Johnson and Johnson Innovative Medicine issued the following news release:
* * *
New clinical data highlights CAPLYTA(R) (lumateperone) as a promising option for achieving remission in adults with major depressive disorder
CAPLYTA(R) nearly doubled the likelihood of remission at six weeks compared to placebo as an adjunctive therapy to an antidepressant based on pooled data from two Phase 3 studies
65% of patient . . .
* * *
New clinical data highlights CAPLYTA(R) (lumateperone) as a promising option for achieving remission in adults with major depressive disorder
CAPLYTA(R) nearly doubled the likelihood of remission at six weeks compared to placebo as an adjunctive therapy to an antidepressant based on pooled data from two Phase 3 studies
65% of patient . . .